Join

Enter Details

Comment on stories, receive email newsletters & alerts.

@
This is your permanent identity for Business Insider Australia
Your email must be valid for account activation
Minimum of 8 standard keyboard characters

Subscribe

Email newsletters but will contain a brief summary of our top stories and news alerts.

Forgotten Password

Enter Details


Back to log in

Tagged With Pharmaceutical

DIGITAL HEALTH BRIEFING: Top trends from HealthConf 2017 -- FDA set to change genetic health risk test regulations -- Australia strengthens digital health record system


Wall Street's most hated drugmaker is getting annihilated after a bizarre conference call


Amazon is making noise in pharma these days -- here's what it could all mean



A furious employee is suing Wall Street's most hated pharma stock over claims about its blockbuster drug


A furious employee is suing drugmaker Mallinckrodt over claims about its $38,000-a-dose blockbuster


Explosive leaked audio reveals the moment a drug company lied about a patient having cancer to get them opioids



Mallinckrodt is getting crushed after a judge invalidated many of its patents


A popular herbal supplement can interfere with many medications, including birth control


Shares in drug maker Indivior tanked almost 40% after losing its heroin treatment copyright case


ANALYST: Most investors respect the Merck CEO's decision to resign from Trump's council


Things are finally really starting to hurt for the maker of EpiPen


One of Trump's best sounding proposals to control drug pricing is a total dud



There's frightening new data on the effects of a blockbuster drug Wall Street loves to hate


Donald Trump just sold us all out on drug pricing


Check out how the shorts have been piling into Wall Street's most hated pharma stock


A Wall Street investor call revealed part of the secret of why drugs are so expensive



States are starting to stand up to 'the new Big Tobacco' because Washington won't


It sounds like the maker of EpiPen is freaking out ahead of a big shareholder meeting


One of the most hated drug companies on Wall Street is facing another nasty probe


Amazon has several hurdles to jump before it could enter pharmaceuticals